Resveratrol improves efficacy of oral amoxicillin against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical trial

Lu, Qiang; Di, Yunfei; Jiang, Zhilan; Xu, Jing

doi:10.1016/j.micpath.2017.11.062

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxyresveratrol (2′,3,4′,5-tetrahydroxystilbene), found in white mulberry ( Morus alba ), exhibited, among other effects, the inhibition of TNF-α production and stronger antioxidant activity than resveratrol [14]. Many of these molecules have been subjected to clinical trials and are being investigated as clinical drugs [15,16,17].…”

Section: Introductionmentioning

confidence: 99%

Metabolism of Stilbenoids by Human Faecal Microbiota

et al. 2019

View full text Add to dashboard Cite

Stilbenoids are dietary phenolics with notable biological effects on humans. Epidemiological, clinical, and nutritional studies from recent years have confirmed the significant biological effects of stilbenoids, such as oxidative stress protection and the prevention of degenerative diseases, including cancer, cardiovascular diseases, and neurodegenerative diseases. Stilbenoids are intensively metabolically transformed by colon microbiota, and their corresponding metabolites might show different or stronger biological activity than their parent molecules. The aim of the present study was to determine the metabolism of six stilbenoids (resveratrol, oxyresveratrol, piceatannol, thunalbene, batatasin III, and pinostilbene), mediated by colon microbiota. Stilbenoids were fermented in an in vitro faecal fermentation system using fresh faeces from five different donors as an inoculum. The samples of metabolized stilbenoids were collected at 0, 2, 4, 8, 24, and 48 h. Significant differences in the microbial transformation among stilbene derivatives were observed by liquid chromatography mass spectrometry (LC/MS). Four stilbenoids (resveratrol, oxyresveratrol, piceatannol and thunalbene) were metabolically transformed by double bond reduction, dihydroxylation, and demethylation, while batatasin III and pinostilbene were stable under conditions simulating the colon environment. Strong inter-individual differences in speed, intensity, and pathways of metabolism were observed among the faecal samples obtained from the donors.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolism of Stilbenoids by Human Faecal Microbiota

et al. 2019

View full text Add to dashboard Cite

show abstract

“…RSV has been investigated in adults of all ages including elderly populations over 70 years, as illustrated by the frequency distribution of mean age per group for individuals that received RSV in each trial (Figure 5B). Furthermore, four separate trials have been conducted in children, assessing the ability of RSV to affect symptoms associated with attention-deficit/hyperactivity disorder [106], autism spectrum disorder [105,149], and fast breathing pneumonia [138].…”

Section: Clinical Indication and Trial Participantsmentioning

confidence: 99%

Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities

Brown,

Theofanous,

Britton

et al. 2024

IJMS

View full text Add to dashboard Cite

Resveratrol has long been proposed as being beneficial to human health across multiple morbidities, yet there is currently no conclusive clinical evidence to advocate its recommendation in any healthcare setting. A large cohort with high-quality clinical data and clearly defined biomarkers or endpoints are required to draw meaningful conclusions. This systematic review compiles every clinical trial conducted using a defined dose of resveratrol in a purified form across multiple morbidities to highlight the current ‘state-of-play’ and knowledge gaps, informing future trial designs to facilitate the realisation of resveratrol’s potential benefits to human health. Over the last 20 years, there have been almost 200 studies evaluating resveratrol across at least 24 indications, including cancer, menopause symptoms, diabetes, metabolic syndrome, and cardiovascular disease. There are currently no consensus treatment regimens for any given condition or endpoint, beyond the fact that resveratrol is generally well-tolerated at a dose of up to 1 g/day. Additionally, resveratrol consistently reduces inflammatory markers and improves aspects of a dysregulated metabolism. In conclusion, over the last 20 years, the increasing weight of clinical evidence suggests resveratrol can benefit human health, but more large, high-quality clinical trials are required to transition this intriguing compound from health food shops to the clinic.

show abstract

“…In the rest of drugs resveratrol, Tretinoin and Simvastatin, our study also strongly recommends all of them for the effective treatment of comorbid diseases of COVID-19. For instance, resveratrol is already under clinical trials against the highly comorbid diseases of COVID-19 such as hypertension, diabetics, pneumonia except ARDS and pulmonary edema 48,49,50,51 .…”

Section: Resveratrol Significantly Reduced Hypoxia Induced Vascular Lmentioning

confidence: 99%

Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19

Patel

Tulswani

Khurana

et al. 2020

Preprint

View full text Add to dashboard Cite

The number of hospitalization of COVID-19 patients with one or more comorbid diseases is highly alarming. Despite the lack of large clinical data and incomplete understanding of virus pathology, identification of the COVID-19 associated diseases with clinical precision are highly limited. In this regard, our text mining of 6238 PubMed abstracts (as on 23 April 2020) successfully identified broad spectrum of COVID-19 comorbid diseases/disorders (54), and their prevalence on the basis of the number of occurrence of disease terms in the abstracts. The disease ontology based semantic similarity network analysis revealed the six highly comorbid diseases of COVID-19 namely Viral Pneumonia, Pulmonary Fibrosis, Pulmonary Edema, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD) and Asthma. The disease gene bipartite network revealed 15 genes that were strongly associated with several viral pathways including the corona viruses may involve in the manifestation (mild to critical) of COVID-19. Our tripartite network- based repurposing of the approved drugs in the world market revealed six promising drugs namely resveratrol, dexamethasone, acetyl cysteine, Tretinoin, simvastatin and aspirin to treat comorbid symptoms of COVID-19 patients. Our animal studies in rats and literatures strongly supported that resveratrol is the most promising drug to possibly reduce several comorbid symptoms associated with COVID-19 including the severe hypoxemia induced vascular leakage. Overall, the anti-viral properties of resveratrol against corona virus could be readily exploited to effectively control the viral load at early stage of COVID-19 infection through nasal administration.

show abstract

Resveratrol improves efficacy of oral amoxicillin against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical trial

Cited by 6 publications

References 24 publications

Metabolism of Stilbenoids by Human Faecal Microbiota

Metabolism of Stilbenoids by Human Faecal Microbiota

Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities

Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19

Contact Info

Product

Resources

About